We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.075 | 0.27% | 27.56 | 27.56 | 27.565 | 27.75 | 27.44 | 27.545 | 83,775 | 11:25:04 |
From Apr 2021 to Apr 2024
By Ed Frankl
Bayer AG said Friday that European drug regulators recommended its finerenone kidney-disease treatment for marketing authorization in the EU.
The German pharmaceutical company said the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency, gave a positive opinion for finerenone as a new treatment of chronic kidney disease associated with type 2 diabetes in adults.
"The positive CHMP opinion for finerenone brings us closer to providing this new treatment option to patients with chronic kidney disease associated with type 2 diabetes," said Christian Rommel, Bayer's head of pharmaceuticals research and development.
The regulatory opinion is based on the results of a Phase 3 study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in more than 13,000 patients.
Finerenone was approved by the U.S. Food and Drug Administration in July 2021 under the brand name Kerendia.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
December 17, 2021 07:59 ET (12:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
